Anavex Life Sciences Corp. AVXL 深 滬
已收盤 01-30 16:00:00 美东时间
4.70
-0.210
-4.28%
華盛通- 最 高5.05
- 今 開4.83
- 成交量 183.44万股
- 最 低 4.68
- 昨 收 4.91
- 總市值 4.04亿
- 52周最高 13.99
- 市盈率 靜 --
- 換手率 2.14%
- 52周最低 2.86
- 委 比 39.09%
- 總股本 8589.38万
- 歷史最高 31.50
- 量 比 2.00
- 振 幅 7.54%
- 歷史最低 0.60
- 每 手 1
- 風險率 2.25%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Anavex Life Sciences Joins ACCESS-AD
Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), today announced its participation as a key industry partner in ACCESS-AD, a major new European initiative designed to accelerate the adoption of
01-13 20:34
美股大行评级 | 拼多多、小鹏获Freedom上调目标价；多家大行首予Wealthfront"超配"评级，目标价最高23美元
今日重点评级关注：HC Wainwright & Co.：维持MetaVia Inc."买入"评级，目标价从12美元升至40美元；Canaccord Genuity：维持GH Research"买入"评级，目标价从35美元升至39美元
01-07 17:25
Anavex Life Sciences To Submit Data On Phase IIb/III ANAVEX2-73-AD-004 Alzheimer's Disease Trial To FDA For New Drug Application
Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia,
01-06 20:33
Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program
Anavex Life Sciences announced that the FDA has invited the company to present its Alzheimer's disease clinical trial results, reflecting interest in its development efforts. The Type C meeting discussed the potential pathways for an NDA submission and the submission of existing Phase IIb/III data. Anavex highlighted blarcamesine's convenience and lack of significant safety concerns. The company remains committed to progressing its Alzheimer's di...
01-06 12:30
EMA recommends rejecting Anavex's blarcamesine for Alzheimer's
The European Medicine Agency is recommending that Anavex Life Sciences' (AVXL) marketing authorization application for Alzheimer's treatment blarcamesine be rejected. The agency said that the princip...
2025-12-12 23:58
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
Anavex Life Sciences Corp.提供关于其在欧盟对药物blarcamesine治疗早期阿尔茨海默病的监管审查的更新。尽管欧洲药品管理局的CHMP委员会最初对营销授权申请持负面意见，但Anavex计划请求重新审查以寻求新的评估机会。公司董事长兼首席执行官表示，将继续与监管机构合作，旨在为患者及其家庭提供潜在的新治疗选择。阿尔茨海默病是全球最常见的痴呆症原因，存在迫切的未满足治疗需求。Anavex的主要候选药物ANAVEX®2-73（blarcamesine）已成功完成多项临床试验，并在治疗阿尔茨海默病及其他中枢神经系统疾病方面显示潜力。该公司致力于推进其研究，以期提供疾病修饰疗法。
2025-12-12 21:05
美股牛股 | 机器人概念股集体爆发！iRobot涨超73%，Richtech Robotics涨超18%；医药股Capricor暴涨超371%
机器人概念股集体爆发！iRobot涨超73%，Richtech Robotics涨超18%，特朗普新政拟All in 机器人；医药股Capricor暴涨超371%，关键实验获重大突破>>
2025-12-04 15:42
美股大行评级 | 美银证券下调哔哩哔哩目标价至31美元；高盛下调诺和诺德目标价至54美元
今日重点评级关注：Benchmark：维持Grupo Televisa"买入"评级，目标价从9美元升至10美元；Truist Securities：维持迪尔股份"买入"评级，目标价从609美元升至612美元
2025-12-01 14:33
SA Quant ranks Goldman's small-cap stocks with largest short interest
Goldman Sachs analysts last week identified 50 small-cap stocks with the highest short interest as a percentage of market cap, a list that was topped by Anavex Life Sciences (AVXL). The brokerage look...
2025-11-27 04:13
Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
<p>Anavex Life Sciences Corp. will present one oral late breaking communication and two poster presentations on blarcamesine at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference in San Diego, December 1-4, 2025. The presentations highlight significant clinical improvements in early Alzheimer’s disease patients, as well as the drug’s potential to slow cognitive decline with a favorable safety profile. The conference, a key event in...
2025-11-26 12:30
